News
Race Oncology (ASX: RAC) is an ASX-listed clinical stage, global biotechnology company with a dedicated mission to be at the heart of cancer care. Race’s lead asset, bisantrene, is a small molecule anthracene chemotherapeutic. Bisantrene has a unique and rich clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, as well characterised safety profile, and compelling clinical data demonstrating an anti-cancer effect and a lack of cardiotoxicity.
Race is developing bisantrene to address the high unmet need of patients across multiple oncology indications, with an initial focus on metastatic breast cancer (lead indication) and acute myeloid leukaemia (AML), exploring anti-cancer plus cardio-protection in synergy with known standards of care.
As part of its clinical program, Race is also investigating the impact bisantrene and new molecules have on the m6A RNA pathway, following independent research describing bisantrene as the most potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of RNA (over expression of FTO) has been shown to be a driver of a diverse range of cancers.
Race Oncology is in collaboration with City of Hope, MD Anderson, Sheba City of Health and UNC School of Medicine, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world. Learn more at www.raceoncology.com
KEY PEOPLE
RELATED STOCKHEAD STORIES
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
Large caps deny they’re being outgunned by smaller peers in health R&D
Health & Biotech
Here’s what we’re getting wrong about the war against cancer
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
ATO blocks biotech access to Jobkeeper wage subsidy
News
It was tough to raise capital in March unless you were a gold explorer
Director Trades
Directors Trades: As the markets keep falling, the directors keep buying
News
Trading Places: The moves substantial holders were making this week
News
Corporate: Eagle Health pounces on another coronavirus opportunity
News
Rise and Shine: What you need to know before the ASX opens
Health & Biotech
WA biotechs are booming; now government wants to make the state a life sciences hub
Health & Biotech
Cancer Wars Part 1: These are the ASX small cap drugmakers that want to conquer cancer
Health & Biotech
Pick of the pods: Best of the Health Kick Podcast in 2019
Director Trades
The most noteworthy directors trades of 2019
Health & Biotech
Health Kick Podcast: Commercialising orphan drugs, the need for better regulation and the ASX’s lifestyle play problem
Health & Biotech
Health: Investment from a DNA sequencer sends Race Oncology flying
News